HOME >> MEDICINE >> NEWS
Alzheimer's pathology reduced, longevity improved in mouse model, Gladstone study shows

Removal of an enzyme that regulates the activity of many proteins can suppress key features of Alzheimer's disease in experimental models, researchers at the Gladstone Institute of Neurological Disease (GIND) recently reported in the Journal of Neuroscience (May 12, 2004).

Using well-established mouse models of Alzheimer's disease, the investigators examined how changing levels of the enzyme Fyn affects key aspects of the disease, including accumulation of large clumps of amyloid proteins in the brain (so-called plaques) and changes in the complex neuronal networks in which memories are formed and stored. Genetic engineering strategies were used to increase or decrease the expression of Fyn, which regulates many other proteins through the attachment of specific groups of atoms known as phosphate groups.

The researchers determined that changing levels of Fyn had no effect on plaque formation or aberrant sprouting (the abnormal growth of nerve terminals, in which neuchemical messages are stored), indicating that these pathologies involve discrete molecular mechanisms. However, they observed that blocking Fyn expression prevented amyloid proteins from damaging synapses, the specialized connections between brain cells, and improved the longevity of mice. (Experimental mice with Alzheimer's-like disease otherwise die prematurely.) In contrast, increasing Fyn in the brain worsened synaptic damage, and also increased the number of premature deaths in the mice.

Loss of synapses and abnormal outgrowth of nerve terminals occur both in people with Alzheimer's disease and in transgenic mice producing human amyloid proteins in the brain (the model used in the study). Humans with the disease, like mice, die prematurely.

"Synaptic degeneration in Alzheimer's disease is like electrical circuits in a computer becoming faulty -- signals can no longer be transmitted through broken connections," says senior author and GIND director Lennart Mucke, MD, who
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-476-2557
University of California - San Francisco
19-May-2004


Page: 1 2

Related medicine news :

1. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
2. Neuronal death and processing of Tau protein in Alzheimers disease
3. Researchers discover link between insulin and Alzheimers
4. New trials for counseling caregivers and patients with Alzheimers begin
5. Marijuana ingredient may stall decline from Alzheimers
6. Drugs used to treat Alzheimers in nursing homes are worsening sufferers illness
7. UT Southwestern doctors track Oklahoma Alzheimers patients via telemedicine
8. Contrary to previous findings, smoking is detrimental to patients with Alzheimers
9. Nanoscale diagnostic sets sights on Alzheimers
10. New test is first step in early detection of Alzheimers disease
11. Older people with the Alzheimers gene find it harder to remember to remember even if healthy

Post Your Comments:
(Date:8/28/2014)... 2014 Kirklyn Smith, an office manager for ... a new world’s record by walking 5,000 miles in a ... constantly amazed by the thousands of individual stories of TrekDesk ... to stand out more than the others. , Kirklyn has ... count which tallies a range of 54,823 steps (presumably on ...
(Date:8/28/2014)... (HealthDay News) -- Lack of sleep not only puts teens ... increased risk for obesity, researchers warn. The study authors ... were aged 16 and 21. Nearly one-fifth of them got ... were age 16, and this group was 20 percent more ... got more than eight hours of sleep per night at ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 NJ ... Institute of North Jersey. , NJ Top Doc, ... is now a certified medical examiner for the ... certified by the department to perform all drug ... training in diagnosing and treating musculoskeletal disorders including ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... August 28, 2014 As Mirena IUD ... around the U.S., Bernstein Liebhard LLP notes that a ... like Mirena as ideal birth control for teenage girls. ... authors of the study point out that IUDs are ... other methods favored by this patient population. Their study, ...
Breaking Medicine News(10 mins):Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. ... company that merged with MabVax Therapeutics, Inc. on ... significant progress related to the development of its ... was recovered using the Company,s internally developed antibody ... potential for multiple antibody based therapeutic and diagnostic ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
Cached News: